The 2011 submarine volcanic eruption in El Hierro (Canary Islands)

Forty years after the Teneguía Volcano (La Palma, 1971), a submarine eruption took place off the town of La Restinga, south of El Hierro, the smallest and youngest island of the Canarian Archipelago. Precursors allowed an early detection of the event and its approximate location, suggesting it was submarine. Uncertainties derived from insufficient scientific information available to the authorities during the eruption, leading to disproportionate civil protection measures, which had an impact on the island's economy-based primarily on tourism-while residents experienced extra fear and distress. © 2012 Blackwell Publishing Ltd, The Geologists' Association & The Geological Society of London.Peer Reviewe

The 2011 submarine volcanic eruption in El Hierro (Canary Islands)

Forty years after the Teneguía Volcano (La Palma, 1971), a submarine eruption took place off the town of La Restinga, south of El Hierro, the smallest and youngest island of the Canarian Archipelago. Precursors allowed an early detection of the event and its approximate location, suggesting it was submarine. Uncertainties derived from insufficient scientific information available to the authorities during the eruption, leading to disproportionate civil protection measures, which had an impact on the island's economy-based primarily on tourism-while residents experienced extra fear and distress. © 2012 Blackwell Publishing Ltd, The Geologists' Association & The Geological Society of London.Peer Reviewe

The ongoing volcanic eruption of El Hierro, Canary Islands

El Hierro, the youngest of the Canary Islands (Spain), is no stranger to hazards associated with volcanic activity or to efforts to minimize the effects of these hazards on local communities. As early as 1793, administrative records of El Hierro indicate that a swarm of earthquakes was felt by locals; fearing a greater volcanic catastrophe, the first evacuation plan of an entire island in the history of the Canaries was prepared. The 1793 eruption was probably submarine with no appreciable consequences other than that the earthquakes were felt [Carracedo, 2008]; over the next roughly 215 years the island was seismically quiet. Yet seismic and volcanic activity are expected on this youngest Canary Island due to its being directly above the presumed location of the Canary Island hot spot, a mantle plume that feeds upwelling magma just under the surface, similar to the Hawaiian Islands. Because of this known geologic activity, the Spanish Instituto Geogrfco Nacional (IGN) has managed geophysical monitoring of the island since the beginning of the 1990s.Peer Reviewe

Identification of black bean (Phaseolus vulgaris L.) genotypes resistant to anthracnose and rust for Veracruz and Chiapas, Mexico

Objective:to determine the reaction of 53 lines and three varieties of black beans to inoculation with Uromyces appendiculatusand Colletotrichum lindemuthianum, to identify genotypes resistant to rust and anthracnose. Design/methodology/approach:ten seedlings of each genotype were inoculated in the greenhouse with a suspension of U. appendiculatusurediospores and another 10 with a suspension of C. lindemuthianumconidia. Fourteen days after inoculation, the reaction of the genotypes to rust was evaluated with a severity scale of 1 to 6, and to anthracnose, with a scale of 0 to 4. The data were analyzed in a completely randomized design with 10 replications per treatment and for the separation of averages the LSD at 0.05 was applied. Results:41 genotypes showed a hypersensitivity reaction to rust, of which 25 had a reaction value of 2.0, statistically lower than that of the controls. In turn, 45 genotypes were resistant to anthracnose, of which 18 had a value of 1.0, statistically similar to that of Negro Jamapa and lower than that of the rest of the genotypes. Limitations of the study/implications:due to the diversity of races of both pathogens, the genotypes were inoculated with monopustular isolates of the main races of U. appendiculatusand with monosporic cultures of C. lindemuthianum, which occur in the bean crops of Veracruz and Chiapas. Findings/conclusions:25 lines resistant to rust and 18 to anthracnose were identified, which stood out for presenting the least damage from these diseases.Objective: to determine the reaction of 53 lines and three varieties of black bean (Phaseolus vulgaris L.) to inoculation with Uromyces appendiculatus and Colletotrichum lindemuthianum, to identify genotypes resistant to rust and anthracnose.Design/methodology/approach: 10 seedlings of each genotype were inoculated in the greenhouse with a suspension of U. appendiculatus uredospores and another 10 with a suspension of C. lindemuthianum conidia. At 14 days after inoculation, the reaction of the genotypes to rust was evaluated with a severity scale of 1 to 6, and to anthracnose, with ascale of 0 to 4. The data were analyzed in a completely randomized design with 10 replications per treatment and LSD at 0.05 was applied for the separation of averages.Results: 41 genotypes showed a hypersensitivity reaction to rust, of which 25 had a reaction value of 2.0, statistically lower than those of controls. In turn, 45 genotypes were resistant to anthracnose, of which 18 had a value of 1.0, statistically similar to that of Negro Jamapa and lower than those of the rest of the genotypes.Study limitations/implications: due to the diversity of races of both pathogens, the genotypes were inoculated with monopustular isolates of the principal races of U. appendiculatus and with monosporic cultures of C. lindemuthianum, which occur in the bean crops of Veracruz and Chiapas.Findings/conclusions: 25 lines resistant to rust and 18 to anthracnose were identified, which stood out for presenting the least damage from these diseases

Development of a Novel Anti-CD19 Chimeric Antigen Receptor : A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdc Il2rd/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients

The 2018 revision of the standard IEC 61400-24 : lightning protection of wind turbines

The first edition of the standard IEC 61400-24, Wind Generator Systems – Part 24 Lightning Protection, was issued in June 2010, and the scope was to reflect the experiences and technical understanding of lightning protection of wind turbines by manufacturers, certification organizations, research institutes and universities. It presented background statistical information on lightning damage to wind turbines, and it provided guidance on lightning protection best practices. Since then, the wind power industry has further developed towards even larger onshore and offshore wind turbines and into a mature industry. This is the background for the current draft of the 2018 revision of the IEC 61400-24, which transforms the 2010 edition into an evolution of the previous issued standard based on improved technical experience and expertise

Efficacy of clozapine versus standard treatment in adult individuals with intellectual disability and treatment-resistant psychosis (CLOZAID): study protocol of a multicenter randomized clinical trial

BackgroundIntellectual disability (ID) affects approximately 1% of the worldwide population and individuals with ID have a higher comorbidity with mental illness, and specifically psychotic disorders. Unfortunately, among individuals with ID, limited research has been conducted since ID individuals are usually excluded from mental illness epidemiological studies and clinical trials. Here we perform a clinical trial to investigate the effectiveness of clozapine in the treatment of resistant psychosis in individuals with ID. The article highlights the complexity of diagnosing and treating psychopathological alterations associated with ID and advocates for more rigorous research in this field.MethodsA Phase IIB, open-label, randomized, multicenter clinical trial (NCT04529226) is currently ongoing to assess the efficacy of oral clozapine in individuals diagnosed with ID and suffering from treatment-resistant psychosis. We aim to recruit one-hundred and fourteen individuals (N=114) with ID and resistant psychosis, who will be randomized to TAU (treatment as usual) and treatment-with-clozapine conditions. As secondary outcomes, changes in other clinical scales (PANSS and SANS) and the improvement in functionality, assessed through changes in the Euro-QoL-5D-5L were assessed. The main outcome variables will be analyzed using generalized linear mixed models (GLMM), assessing the effects of status variable (TAU vs. Clozapine), time, and the interaction between them.DiscussionThe treatment of resistant psychosis among ID individuals must be directed by empirically supported research. CLOZAID clinical trial may provide relevant information about clinical guidelines to optimally treat adults with ID and treatment-resistant psychosis and the benefits and risks of an early use of clozapine in this underrepresented population in clinical trials.Trial registrationClinicaltrials.gov: NCT04529226. EudraCT: 2020-000091-37